Literature DB >> 10325817

Antibody response to accelerated Hib immunisation in preterm infants receiving dexamethasone for chronic lung disease.

M J Robinson1, F Campbell, P Powell, D Sims, C Thornton.   

Abstract

AIM: To study the effect of dexamethasone on the routine immunisation of preterm infants with chronic lung disease.
METHODS: Serum samples were obtained before and after immunisation from an unselected cohort of 59 preterm infants. Haemophilus influenzae antibodies were measured using an ELISA method and differences in the geometric mean values between the two groups of babies analysed.
RESULTS: Sixteen infants received no dexamethasone. Before and after immunisation antibody titres for those receiving no dexamethasone were 0.16 and 4.63 mcg IgG/ml. Corresponding values for those receiving dexamethasone were 0.10 and 0.51 mcg IgG/ml, respectively.
CONCLUSION: Dexamethasone used in the treatment of chronic lung disease seems to significantly affect the antibody response of preterm infants to immunisation against Haemophilus influenzae.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10325817      PMCID: PMC1720881          DOI: 10.1136/fn.80.1.f69

Source DB:  PubMed          Journal:  Arch Dis Child Fetal Neonatal Ed        ISSN: 1359-2998            Impact factor:   5.747


  15 in total

1.  Protective levels of serum antibodies stimulated in infants by two injections of Haemophilus influenzae type b capsular polysaccharide-tetanus toxoid conjugate.

Authors:  B A Claesson; R Schneerson; J B Robbins; J Johansson; T Lagergard; J Taranger; D Bryla; L Levi; T Cramton; B Trollfors
Journal:  J Pediatr       Date:  1989-01       Impact factor: 4.406

2.  Immunogenicity and safety of PRP-T conjugate vaccine given according to the British accelerated immunisation schedule.

Authors:  R Booy; S A Taylor; S R Dobson; D Isaacs; G Sleight; S Aitken; H Griffiths; H Chapel; R T Mayon-White; J A Macfarlane
Journal:  Arch Dis Child       Date:  1992-04       Impact factor: 3.791

3.  Prevention of Hemophilus influenzae type b bacteremic infections with the capsular polysaccharide vaccine.

Authors:  H Peltola; H Käyhty; M Virtanen; P H Mäkelä
Journal:  N Engl J Med       Date:  1984-06-14       Impact factor: 91.245

4.  Immunologic response to early and routine DTP immunization in infants.

Authors:  L J Baraff; R D Leake; D G Burstyn; T Payne; C L Cody; C R Manclark; J W St Geme
Journal:  Pediatrics       Date:  1984-01       Impact factor: 7.124

5.  The protective level of serum antibodies to the capsular polysaccharide of Haemophilus influenzae type b.

Authors:  H Käyhty; H Peltola; V Karanko; P H Mäkelä
Journal:  J Infect Dis       Date:  1983-06       Impact factor: 5.226

6.  Combined diphtheria, tetanus, pertussis, and Haemophilus influenzae type b vaccines for primary immunisation.

Authors:  F Bell; A Martin; C Blondeau; C Thornton; J Chaplais; A Finn
Journal:  Arch Dis Child       Date:  1996-10       Impact factor: 3.791

7.  Antibody response to accelerated immunisation with diphtheria, tetanus, pertussis vaccine.

Authors:  M E Ramsay; M Rao; N T Begg; K Redhead; A M Attwell
Journal:  Lancet       Date:  1993-07-24       Impact factor: 79.321

8.  Persistence of antibody after accelerated immunisation with diphtheria/tetanus/pertussis vaccine.

Authors:  M E Ramsay; M J Corbel; K Redhead; L A Ashworth; N T Begg
Journal:  BMJ       Date:  1991-06-22

9.  Immunogenicity of combined diphtheria, tetanus, and pertussis vaccine given at 2, 3, and 4 months versus 3, 5, and 9 months of age.

Authors:  R Booy; S J Aitken; S Taylor; G Tudor-Williams; J A Macfarlane; E R Moxon; L A Ashworth; R T Mayon-White; H Griffiths; H M Chapel
Journal:  Lancet       Date:  1992-02-29       Impact factor: 79.321

10.  Induction of serum Haemophilus influenzae type B capsular antibodies in adult volunteers fed cross-reacting Escherichia coli 075:K100:H5.

Authors:  R Schneerson; J B Robbins
Journal:  N Engl J Med       Date:  1975-05-22       Impact factor: 91.245

View more
  8 in total

1.  Effect of a fourth Haemophilus influenzae type b immunisation in preterm infants who received dexamethasone for chronic lung disease.

Authors:  P Clarke; P J Powell; D Goldblatt; M J Robinson
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2003-01       Impact factor: 5.747

Review 2.  Immunization of preterm infants.

Authors:  Arnaud Gagneur; Didier Pinquier; Caroline Quach
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

Review 3.  Immunisation of premature infants.

Authors:  J Bonhoeffer; C-A Siegrist; P T Heath
Journal:  Arch Dis Child       Date:  2006-11       Impact factor: 3.791

Review 4.  Factors That Influence the Immune Response to Vaccination.

Authors:  Petra Zimmermann; Nigel Curtis
Journal:  Clin Microbiol Rev       Date:  2019-03-13       Impact factor: 26.132

Review 5.  Active immunization of premature and low birth-weight infants: a review of immunogenicity, efficacy, and tolerability.

Authors:  Carl T D'Angio
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

6.  Hib vaccination in infants born prematurely.

Authors:  P T Heath; R Booy; J McVernon; J Bowen-Morris; H Griffiths; M P E Slack; A C Moloney; M E Ramsay; E R Moxon
Journal:  Arch Dis Child       Date:  2003-03       Impact factor: 3.791

7.  Acellular pertussis vaccine given by accelerated schedule: response of preterm infants.

Authors:  M H Slack; D Schapira; R J Thwaites; C Schapira; J Bamber; M Burrage; J Southern; N Andrews; E Miller
Journal:  Arch Dis Child Fetal Neonatal Ed       Date:  2004-01       Impact factor: 5.747

8.  Heptavalent pneumococcal conjugate vaccine immunogenicity in very-low-birth-weight, premature infants.

Authors:  Carl T D'Angio; Roy J Heyne; T Michael O'Shea; Robert L Schelonka; Seetha Shankaran; Shahnaz Duara; Ronald N Goldberg; Barbara J Stoll; Krisa P Van Meurs; Betty R Vohr; Abhik Das; Lei Li; Robert L Burton; Betty Hastings; Dale L Phelps; Pablo J Sanchez; Waldemar A Carlo; David K Stevenson; Rosemary D Higgins
Journal:  Pediatr Infect Dis J       Date:  2010-07       Impact factor: 2.129

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.